Acute-On-Chronic Liver Failure
Conditions
Brief summary
The subjects of this study were inpatients with ACLF who were admitted to Tongji Hospital in Wuhan from March 2023 to June 2025. After patients were enrolled, The patient's general information (gender, age, past medical history, etc.), complications (ascites, hepatic encephalopathy, hepatorenal syndrome, gastrointestinal bleeding, etc.), laboratory tests (CRP, PCT, INR, WBC, fungal/bacterial diagnostic tests, etc.), symptoms and signs at the time of infection, and at admission (D1), D4, D7, D14, D21, etc.) were recorded Save the blood separately. The patients were divided into fungal infection group, bacterial infection group and non-infection group according to the infection status after admission.
Interventions
None listed
Sponsors
Qin Ning
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. TBIL ≥ 12 mg/mL and INR ≥ 1.5 2. Chronic hepatitis B
Exclusion criteria
(1) \<18 or \>80 years old; (2) primary hepatic or extrahepatic carcinoma; (3) with severe diseases of other organs or systems; (4) pregnancy; (5) imcomplete information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| incidence rate of bacterial or fungal infection | 28 days and 90 days | incidence rate of bacterial or fungal infection |
| mortality rate of bacterial or fungal infection | 28 days and 90 days | mortality rate of bacterial or fungal infection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidence rate of complications | 28 days and 90 days | incidence rate of complications |
Countries
China
Contacts
Primary ContactTao Chen, Professor
Outcome results
None listed